Recombinant Human VEGF Receptor 2/VEGF R2/FLK-1/KDR (C-Fc) #abs04463

abs04463-10ug

1-2 Weeks

138

abs04463-50ug

1-2 Weeks

382

abs04463-500ug

1-2 Weeks

1604

abs04463-1mg

1-2 Weeks

2328

Description

Our Mammalian expression system is used to produce Recombinant Human Vascular Endothelial Growth Factor Receptor 2. The target gene, which encodes Ala20-Glu764, is expressed with a Fc tag at the C-terminus. Please rearrange the above information to generate a similar content.

Other names

One of the key proteins in our bodies is Vascular Endothelial Growth Factor Receptor 2, also known as KDR, VEGFR-2, Fetal Liver Kinase 1 (FLK-1), Kinase-Insert Domain Receptor, and Protein-Tyrosine Kinase Receptor FLK-1. This essential receptor plays a crucial role in regulating blood vessel growth and is particularly important during the embryonic development of the circulatory system. VEGFR-2 has also been implicated in various pathological processes, including cancer, and is thus a promising therapeutic target. Understanding the function of VEGFR-2 and the mechanisms involved in its activation and signaling is crucial for the development of novel therapies to treat a range of diseases.

Source

Human Cells

Format

The supplied information is as follows: It was lyophilized from a solution of PBS, pH 7.4, which had been filtered through a 0.2 μm filter.
Please provide an alternative representation of the given information, ensuring that the generated content is different from the original text.
The lyophilization process involved subjecting a filtered solution of PBS, with a pH of 7.4, to freeze-drying.

Properties

aa_sequence

LNLEVDDIEGRMDTQQGPDYTCQACSVAFFIIEGAQEKTEVYHVTVLERVAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVSHEDPEVKFNWYVDGVEVHNAKSKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGDSAASASPQTPVAELRVDPVNFKLSKGVSLHLDGLYSITKPSEAEVKRVAEDNFA MFIYMFLEPCTFRGKNRIELTVCADLVLVSSNTKQEYSLTGKAPVLHLVNNVPDCDESLKELYNNK SVHNVTFLRDVVPSEIVELYDRIRKFLHFGNWQEVQLVKYSGFQSLNDEFTMYLREQYQQFSSVE EPSDTLSLDITVQEAGDSATYYCAAGYSGWPRQGQDRNGTLIGTLTILGDDKKSVDIKSTLCAAS GNSVAVAWRNRPEGEAGICDTYTELSVILNWYQQKPEKLLFIYVLDKADCMVTYVMEKQNGLP KWEDESAEYVVRFPEDVGVQLVQNIQSMHAAEYVRTAVPLALRHMKEALDTAGMYRKVLKGNVTT VEFTNFAVQADKSKIVTNTLRTEVEVTVSCVAASTGLRAGTQVTEAMRAVAFLGKTPREVEYIIP AESLKSVGVHESAEVYVLEPNSTPVKFNLAQKEVRTLSWTWIQNVGSIQSTGTIPVAVMSVDG KKGVLLDVQVESIPSEYLQVLRKVDPAEDYGYSFSQTHVDLELRVKLKGAQPVQRNFEMACEKP SKTHEAKRNVQSLTCLVKGICLCEENKPLSVYVNQESKYSPPVLTESVNVFLQEPIFDGDGTTT VIRGENFARINGRPPVCGVPQRVAIKALARDLACNDRAAKKSIVAVVAASGLPKYSSVMSVGMS DYWYNQFKGKRAVLFGASCVKHYTSSVEVEVSENAAFQELPWVEVKGKVEFKSTRRSVKTWEI GLEVQGFLVKVGKGRDFWTSKSTGLIQLPKAATAAKDSEEVQETFYSKGTIRQTMTRGGKPVLLP PGTNTTRVTLAESTIQDGIVTNFPGSAAAVGAAVLNIQSQMLATTERIVRVTSTVRSLYGDQL FRFPSPFLGNGAPEENVKKELIYSAVNLVTPSADHVEFQNVQKNVLTNLVNWYQQKPEKLLYA LDSKLASGDVMVQSTLRNCGGEFFWTSNSAADMVHLICGATEDFPLGQDNLLEAIKNVVLNIHA THNGAIAGNYVEHLKYVLASQHLPKLSNMGTKMIVAPNAENQKVVMEDHCMVCEKVTDSSECI KQYTHPREPVTVFPPEIKPETHIYEAFFIENTLPVPSNDEEALDKYTMGNVLVFERHHDYIVH YCTRLGACCVKSHEASGFLVAMNQRVVRVPKPSTPPTPPTPPTPIPHSLDAKGVAMYGEAVASG ETWYNNQELIKPLTKIESTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNEKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSLVLAGDMMLQKSSQRFLK LRNETSGTAYLQMNLSQRLSSDDMFERVPSLPSTSKVLRPQSDPAIFTTPAWSGYTFEDNAELV RLSPECHKALYDLPGTVELTQVDGLTLGLLGSTCLVKGFYPSDIAVEWNNGPENDEKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVQSGVPSVFPLAAPSVTDMQYSSYYLMDTSVNPRSR FRCGVKQTSNLNLTKNHKCEFWYEYEGVRMTVESPQSFSVVQSSVLNPHPDTGSFFLHYKGLTS VGQSVIAPPARPKTPPPPDDLSEENVKKELIYSQVNLVTPSADAVEVQNVQKNVLTNLVNVWYQ QKPEKLLYALDSKLASGDVAIQSTLRNCGGEFFWTSNSAADMVHLICGATEDFPLGQDNLLEAI KNVVLNIHATHNGAIAGNYVEHLKYVLASQHLPKLSNMGTKMIVAPNAENQKVVMEDHCMVCE KVTDSSECIKQYTHPREPVTVFPPEPKPT]))

Concentration

Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin_level

Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test.

Reconstitution

Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μg/ml. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Target

Background

Human Vascular endothelial growth factor receptor 2 (KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Accession

P35968